New Guidance on Environmental Control of Candida auris with Antimicrobial Pesticides

Last fall the Centers for Disease Control and Prevention (CDC) identified drug resistant Candida auris infections in hospitals in the United States. At that time, CDC issued a clinical alert on Candida to U.S. healthcare facilities and has recently revised its recommendation to include thorough daily and after-discharge cleaning of rooms of C. auris patients using EPA-registered hospital disinfectants active against Clostridium difficile. The previous recommendation was to use a hospital disinfectant effective against fungi. CDC’s disinfection recommendations for C. auris will continue to be updated as new information becomes available.

Drug resistant C. auris is a fungus that poses a global health threat and may cause serious and sometimes fatal fungal infections. C. auris infections tend to occur in hospitalized patients and can be resistant to antifungal drugs. Continue reading

Clostridium difficile – Guidance and Methods for Antimicrobial Efficacy Testing

The Environmental Protection Agency (EPA) is announcing the availability for public comment of two proposed test methods and associated testing guidance for evaluating the effectiveness of antimicrobial pesticides against Clostridium difficile (C. diff).

C. diff is an anaerobic, spore-forming bacterium and a frequent cause of hospital-acquired infections. EPA recognizes the potential public health implications of C. difficile and recommends specific laboratory methodologies to produce and store spores, apply the spores to a hard non-porous surface, and evaluate the effectiveness of antimicrobial products intended to treat these surfaces. Continue reading